Influence of ranibizumab treatment on the extracellular matrix in patients with neovascular age-related macular degeneration

Background We know the influence of the intravitreal anti-vascular endothelial growth factor (VEGF) injections on the choroidal neovascularization in the course of exudative age-related macular degeneration (AMD). However, the influence of the ranibizumab therapy in question on the extracellular matrix (ECM) remains unknown. We aimed to estimate the influence of Lucentis intravitreal injections on the gene expression of structural components of the extracellular matrix in patients with neovascular AMD. Material/Methods Patients with subfoveal localization of neovascularization in AMD, which was clinically active and observed using optical coherence tomography, were treated with ranibizumab (0.5 mg/0.05 mL) in accordance with the PrONTO scheme. Total RNA was extracted from peripheral blood mononuclear cells, and an oligonucleotide microarray technique enabled comparison of the expression level of genes encoding collagens, elastin, and laminins in AMD patients compared to control subjects. Results After 3 intravitreal injections of ranibizumab (Lucentis), COL1A1 and COL6A1 genes showed increased expression, whereas decreased expression mainly occurred for the following genes: COL4A5, COL11A1, COL4A6, LAMB4, and LAMC2. Conclusions Anti-VEGF local therapy influences the gene expression of structural components of the ECM as measured from blood samples. The loading dose of ranibizumab for the retina changes the expression of collagen and laminin genes, but does not influence the expression of the elastin gene.

[1]  A. Laties,et al.  Collagen: A potential factor involved in the pathogenesis of glaucoma , 2013, Medical science monitor basic research.

[2]  M. Figurska.  Retinal pigment epithelial tears following ranibizumab therapy for fibrovascular retinal pigment epithelial detachment due to occult age-related macular degeneration , 2012, Medical science monitor : international medical journal of experimental and clinical research.

[3]  M. Figurska,et al.  Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[4]  Seungbum Kang,et al.  Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration , 2011, Japanese Journal of Ophthalmology.

[5]  Shane T. Jensen,et al.  Mapping structural landmarks, ligand binding sites, and missense mutations to the collagen IV heterotrimers predicts major functional domains, novel interactions, and variation in phenotypes in inherited diseases affecting basement membranes , 2011, Human mutation.

[6]  C. Meyer,et al.  Macular hole formation in the presence of a pigment epithelial detachment after three consecutive intravitreal antivascular endothelial growth factor injections. , 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[7]  A. Padovani,et al.  Role of COL4A1 in basement-membrane integrity and cerebral small-vessel disease. The COL4A1 stroke syndrome. , 2010, Current medicinal chemistry.

[8]  A. Popel,et al.  A peptide derived from type 1 thrombospondin repeat-containing protein WISP-1 inhibits corneal and choroidal neovascularization. , 2009, Investigative ophthalmology & visual science.

[9]  L. Yannuzzi,et al.  Vitreomacular adhesion in active and end-stage age-related macular degeneration. , 2009, American journal of ophthalmology.

[10]  P. Mitchell,et al.  Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials , 2009, British Journal of Ophthalmology.

[11]  R. Krishnan,et al.  Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization , 2009, Clinical & experimental ophthalmology.

[12]  C. Eckardt,et al.  New Components of ‘Basal Laminar Deposits’ in Age-Related Macular Degeneration , 2008, Cells Tissues Organs.

[13]  Shawn M. Sweeney,et al.  Candidate Cell and Matrix Interaction Domains on the Collagen Fibril, the Predominant Protein of Vertebrates* , 2008, Journal of Biological Chemistry.

[14]  M. Bartoli,et al.  Vascular endothelial growth factor in eye disease , 2008, Progress in Retinal and Eye Research.

[15]  J. Miner.  Laminins and their roles in mammals , 2008, Microscopy research and technique.

[16]  B. Hudson,et al.  Mammalian collagen IV , 2008, Microscopy research and technique.

[17]  R. Kalluri,et al.  Type IV collagen-derived angiogenesis inhibitors. , 2007, Microvascular research.

[18]  P. Yurchenco,et al.  Role of Laminin Terminal Globular Domains in Basement Membrane Assembly* , 2007, Journal of Biological Chemistry.

[19]  F. Glorieux,et al.  Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans , 2007, Human mutation.

[20]  M. Killingsworth,et al.  Relationship of Basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration. , 2007, Investigative ophthalmology & visual science.

[21]  A. Negi,et al.  The Upregulation of Angiogenic Gene Expression in Cultured Retinal Pigment Epithelial Cells Grown on Type I Collagen , 2007, Current eye research.

[22]  R. Bhisitkul.  Vascular endothelial growth factor biology: clinical implications for ocular treatments , 2006, British Journal of Ophthalmology.

[23]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[24]  S. Mennel,et al.  Vitreomacular traction, macular hole formation, and subfoveal choroidal neovascularization in a patient with age-related macular degeneration , 2006, Eye.

[25]  Peter M. G. Munro,et al.  Structural correlation between collagen VI microfibrils and collagen VI banded aggregates. , 2006, Journal of structural biology.

[26]  Gillian Murphy,et al.  Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.

[27]  K. Csaky,et al.  Nonlethal oxidant injury to human retinal pigment epithelium cells causes cell membrane blebbing but decreased MMP-2 activity. , 2005, Investigative ophthalmology & visual science.

[28]  R. Hansen,et al.  Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.

[29]  Eero Vuorio,et al.  Collagens and collagen-related matrix components in the human and mouse eye , 2004, Progress in Retinal and Eye Research.

[30]  J. Marshall,et al.  The influence of path length and matrix components on ageing characteristics of transport between the choroid and the outer retina. , 2004, Investigative ophthalmology & visual science.

[31]  U. Schlötzer-Schrehardt,et al.  Collagen IV is essential for basement membrane stability but dispensable for initiation of its assembly during early development , 2004, Development.

[32]  M. Zarbin.  Current concepts in the pathogenesis of age-related macular degeneration. , 2004, Archives of ophthalmology.

[33]  J. Hooymans,et al.  Age-related liquefaction of the human vitreous body: LM and TEM evaluation of the role of proteoglycans and collagen. , 2003, Investigative ophthalmology & visual science.

[34]  R. Visse,et al.  Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry , 2003, Circulation research.

[35]  Paul Mitchell,et al.  Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort. , 2003, Archives of ophthalmology.

[36]  D. Henson,et al.  Age-dependent changes in the basal retinovitreous adhesion. , 2003, Investigative ophthalmology & visual science.

[37]  J. Handa,et al.  Distribution of the collagen IV isoforms in human Bruch’s membrane , 2003, The British journal of ophthalmology.

[38]  Huub Schellekens,et al.  Immunogenicity of therapeutic proteins: clinical implications and future prospects. , 2002, Clinical therapeutics.

[39]  R. Hynes.  A reevaluation of integrins as regulators of angiogenesis , 2002, Nature Medicine.

[40]  K. Tryggvason,et al.  Laminin isoforms in tumor invasion, angiogenesis and metastasis. , 2002, Seminars in cancer biology.

[41]  J. Marshall,et al.  Expression of metalloproteinases from human retinal pigment epithelial cells and their effects on the hydraulic conductivity of Bruch's membrane. , 2002, Investigative ophthalmology & visual science.

[42]  G. Murphy,et al.  Gelatinases A and B. , 2002, Methods in enzymology.

[43]  Z. Werb,et al.  The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. , 2001, Trends in cell biology.

[44]  C. Jackson,et al.  Human endothelial gelatinases and angiogenesis. , 2001, The international journal of biochemistry & cell biology.

[45]  Jiahua Xu,et al.  Rac1 Mediates Type I Collagen-dependent MMP-2 Activation , 2001, The Journal of Biological Chemistry.

[46]  K. Kivirikko,et al.  Collagens and collagen-related diseases , 2001, Annals of medicine.

[47]  P. Harper,et al.  Variation in the vitreous phenotype of Stickler syndrome can be caused by different amino acid substitutions in the X position of the type II collagen Gly-X-Y triple helix. , 2000, American journal of human genetics.

[48]  J. Couchman,et al.  Still More Complexity in Mammalian Basement Membranes , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[49]  S. Seregard,et al.  Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. , 1998, Investigative ophthalmology & visual science.

[50]  M. Meisler,et al.  Marshall syndrome associated with a splicing defect at the COL11A1 locus. , 1998, American journal of human genetics.

[51]  S. Ayad,et al.  Type VI collagen is present in human and bovine vitreous , 1996, Graefe's Archive for Clinical and Experimental Ophthalmology.

[52]  J. Kleman,et al.  Another look at collagen V and XI molecules. , 1995, Matrix biology : journal of the International Society for Matrix Biology.

[53]  S. Ayad,et al.  Extraction and characterization of the tissue forms of collagen types II and IX from bovine vitreous. , 1994, The Biochemical journal.

[54]  R. Mayne,et al.  Isolation and characterization of the chains of type V/type XI collagen present in bovine vitreous. , 1993, The Journal of biological chemistry.

[55]  K. Korach,et al.  Estrogen receptor beta protects against in vivo injury in RPE cells. , 2010, Experimental eye research.

[56]  L. Bruckner-Tuderman,et al.  Basement membranes and human disease , 2009, Cell and Tissue Research.

[57]  Philip J Rosenfeld,et al.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.

[58]  Usha Chakravarthy,et al.  The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. , 2008, Ophthalmology.

[59]  Ranibizumab , 2008, Prescrire international.

[60]  William J Feuer,et al.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.

[61]  A. Ramé.  [Age-related macular degeneration]. , 2006, Revue de l'infirmiere.

[62]  P.T.V.M. de Jong,et al.  Mechanisms of disease: Age-related macular degeneration , 2006 .

[63]  Jie Li,et al.  Angiogenesis in wound repair: Angiogenic growth factors and the extracellular matrix , 2003, Microscopy research and technique.

[64]  Peter M. G. Munro,et al.  Analysis of the collagen VI assemblies associated with Sorsby's fundus dystrophy. , 2002, Journal of structural biology.

[65]  R. Klein,et al.  The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. , 1997, Ophthalmology.